Centessa Pharmaceuticals plc (LON:0ACX)

Centessa Pharmaceuticals Statistics

Total Valuation

LON:0ACX has a market cap or net worth of GBP 2.52 billion. The enterprise value is 2.43 billion.

Market Cap	2.52B
Enterprise Value	2.43B

Important Dates

The next estimated earnings date is Friday, March 27, 2026.

Earnings Date	Mar 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+25.82%
Shares Change (QoQ)	+0.36%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	86.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	226.04
PB Ratio	11.24
P/TBV Ratio	11.24
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-13.45
EV / Sales	220.91
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-18.02

Financial Position

The company has a current ratio of 10.57, with a Debt / Equity ratio of 0.39.

Current Ratio	10.57
Quick Ratio	10.25
Debt / Equity	0.39
Debt / EBITDA	n/a
Debt / FCF	-0.65
Interest Coverage	-19.21

Financial Efficiency

Return on equity (ROE) is -60.62% and return on invested capital (ROIC) is -26.63%.

Return on Equity (ROE)	-60.62%
Return on Assets (ROA)	-25.26%
Return on Invested Capital (ROIC)	-26.63%
Return on Capital Employed (ROCE)	-51.00%
Weighted Average Cost of Capital (WACC)	12.72%
Revenue Per Employee	97,887
Profits Per Employee	-1.58M
Employee Count	114
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

In the past 12 months, LON:0ACX has paid 2.52 million in taxes.

Income Tax	2.52M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +32.49% in the last 52 weeks. The beta is 1.57, so LON:0ACX's price volatility has been higher than the market average.

Beta (5Y)	1.57
52-Week Price Change	+32.49%
50-Day Moving Average	25.37
200-Day Moving Average	19.79
Relative Strength Index (RSI)	45.99
Average Volume (20 Days)	377

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.82

Income Statement

In the last 12 months, LON:0ACX had revenue of GBP 11.16 million and -180.55 million in losses. Loss per share was -1.35.

Revenue	11.16M
Gross Profit	11.16M
Operating Income	-159.05M
Pretax Income	-178.03M
Net Income	-180.55M
EBITDA	-158.82M
EBIT	-159.05M
Loss Per Share	-1.35

Balance Sheet

The company has 183.17 million in cash and 87.98 million in debt, with a net cash position of 95.19 million.

Cash & Cash Equivalents	183.17M
Total Debt	87.98M
Net Cash	95.19M
Net Cash Per Share	n/a
Equity (Book Value)	224.35M
Book Value Per Share	1.67
Working Capital	207.23M

Cash Flow

In the last 12 months, operating cash flow was -134.51 million and capital expenditures -267,818, giving a free cash flow of -134.78 million.

Operating Cash Flow	-134.51M
Capital Expenditures	-267,818
Free Cash Flow	-134.78M
FCF Per Share	n/a

Margins

Gross Margin	100.00%
Operating Margin	-1,425.33%
Pretax Margin	-1,595.38%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:0ACX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-25.82%
Shareholder Yield	-25.82%
Earnings Yield	-7.16%
FCF Yield	-5.34%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0ACX has an Altman Z-Score of 4.29 and a Piotroski F-Score of 2.

Altman Z-Score	4.29
Piotroski F-Score	2